Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

NCT05656469 · View on ClinicalTrials.gov ↗

Study Summary

A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders.

Interventions

  • OTHER Personalised medication advice based on pharmacogenetic testing

Study Locations (9)

Other

  • University Hospital Bonn, Department of Psychiatry and Psychotherapy — Bonn
  • Ludwig-Maximilian University, University Hospital, Institute of Psychiatric Phenomics and Genomics (IPPG) — München
  • Parnassia Psychiatric Institute, Department of Psychiatry — Amsterdam
  • Maastricht University, Department of Psychiatry and Neuropsychology — Maastricht
  • Babeş-Bolyai University, Department of Clinical Psychology and Psychotherapy — Cluj-Napoca
  • University of Belgrade, Faculty of Pharmacy — Belgrade
  • Fundació Clínic per a la Recerca Biomèdica, Department of Psychiatry and Psychology, Hospital Clínic — Barcelona
  • King's College, Institute of Psychiatry, Psychology & Neuroscience — London

New York

  • SUNY Upstate Medical University, Department of Psychiatry and Behavioural Sciences — Syracuse

Trial Details

FieldValue
Enrollment Target 2,500 participants
Start Date 2023-02-23
Est. Completion 2026-09
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05656469

The ClinicalTrials.gov registry entry for NCT05656469 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Maastricht University Medical Center, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 1 intervention — of which Personalised medication advice based on pharmacogenetic testing is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05656469 reports 9 study locations spanning 2 distinct geographic areas — top geographies include Other, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05656469 about?

NCT05656469 is a clinical study titled "Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders". A 24-week, patient- and rater-blinded, two-arm, parallel-group controlled, and multi-centre randomized clinical trial (RCT) to establish the benefits of pharmacogenetics-informed pharmacotherapy versus dosing as usual (DAU) in psychiatric patients suffering from mood, anxiety, or psychotic disorders...

What is the current status of trial NCT05656469?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2023-02-23. Estimated completion is 2026-09.

What conditions does trial NCT05656469 study?

This clinical trial studies the following conditions: Anxiety Disorders, Mood Disorders, Psychotic Disorders. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05656469?

The interventions under investigation include: Personalised medication advice based on pharmacogenetic testing (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05656469?

This trial is sponsored by Maastricht University Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05656469 being conducted?

This trial has 9 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial